|
||||||
Executive Summary Acute Respiratory Distress Syndrome-Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2018, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape. Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 6, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory). - The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Read More Contact Us:
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Acute Respiratory Distress Syndrome-Overview Acute Respiratory Distress Syndrome-Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Acute Respiratory Distress Syndrome-Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Acute Respiratory Distress Syndrome-Companies Involved in Therapeutics Development Athersys Inc Bayer AG Cells for Cells SA Commence Bio Inc CompleGen Inc Cynata Therapeutics Ltd Faron Pharmaceuticals Oy GlaxoSmithKline Plc Hydra Biosciences Inc Implicit Bioscience Ltd PaxVax Inc ProMetic Life Sciences Inc Savara Inc SolAeroMed Inc Windtree Therapeutics Inc Acute Respiratory Distress Syndrome-Drug Profiles Aerosurf-Drug Profile Product Description Mechanism Of Action R&D Progress BIO-10901-Drug Profile Product Description Mechanism Of Action R&D Progress CGX-1037-Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2586881-Drug Profile Product Description Mechanism Of Action R&D Progress HC-067047-Drug Profile Product Description Mechanism Of Action R&D Progress IC-14-Drug Profile Product Description Mechanism Of Action R&D Progress imatinib mesylate-Drug Profile Product Description Mechanism Of Action R&D Progress interferon beta-1a-Drug Profile Product Description Mechanism Of Action R&D Progress IO-2-Drug Profile Product Description Mechanism Of Action R&D Progress LT-1001-Drug Profile Product Description Mechanism Of Action R&D Progress molgramostim-Drug Profile Product Description Mechanism Of Action R&D Progress MSC-2-Drug Profile Product Description Mechanism Of Action R&D Progress Multistem-Drug Profile Product Description Mechanism Of Action R&D Progress NAV-5093-Drug Profile Product Description Mechanism Of Action R&D Progress NAV-5188-Drug Profile Product Description Mechanism Of Action R&D Progress Peptide for Acute Respiratory Distress Syndrome-Drug Profile Product Description Mechanism Of Action R&D Progress plasminogen (human)-Drug Profile Product Description Mechanism Of Action R&D Progress PXVX-0047-Drug Profile Product Description Mechanism Of Action R&D Progress S-1229-Drug Profile Product Description Mechanism Of Action R&D Progress SAN-101-Drug Profile Product Description Mechanism Of Action R&D Progress simvastatin-Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome-Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Acute Respiratory Distress Syndrome and Sepsis-Drug Profile Product Description Mechanism Of Action R&D Progress TCP-25-Drug Profile Product Description Mechanism Of Action R&D Progress Acute Respiratory Distress Syndrome-Dormant Projects Acute Respiratory Distress Syndrome-Discontinued Products Acute Respiratory Distress Syndrome-Product Development Milestones Featured News & Press Releases Jun 14, 2018: Faron Pharmaceuticals: Traumakine biomarker analysis of the Phase III INTEREST trial May 11, 2018: Faron Pharmaceuticals : Update on the Phase III INTEREST trial of Traumakine in the treatment of ARDS May 08, 2018: Faron announces top line data from the Phase III INTEREST trial with Traumakine in the treatment of ARDS Feb 05, 2018: Faron establishes second Traumakine manufacturing site Jan 29, 2018: FDA grants Fast Track Designation to Faron for Traumakine Jan 24, 2018: FDA has approved Faron's Traumakine IND Dec 11, 2017: The patient recruiting of the Traumakinen INTEREST study has ended Dec 01, 2017: Appointment of Chief Commercial Officer Oct 02, 2017: Farons Traumakine Receives Promising Innovative Medicine Designation from the MHRA for the Treatment of ARDS Sep 04, 2017: Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine following completion of European and Japanese Phase III studies Aug 04, 2017: Faron Pharmaceuticals: IDMC recommends Traumakine Phase III ARDS study to continue as planned May 08, 2017: Faron Pharmaceuticals: Update on INTEREST Phase III Study for Traumakine in ARDS from IDMC Apr 25, 2017: Navigen Announces USD1.7MM Phase II NIH SBIR Award to Support the Development of ARF6 Inhibitors for Treatment of Acute Lung Injury Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Figures Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2018 Number of Products under Development by Companies, H2 2018 Number of Products by Top 10 Targets, H2 2018 Number of Products by Stage and Top 10 Targets, H2 2018 Number of Products by Top 10 Mechanism of Actions, H2 2018 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 Number of Products by Routes of Administration, H2 2018 Number of Products by Stage and Routes of Administration, H2 2018 Number of Products by Molecule Types, H2 2018 Number of Products by Stage and Molecule Types, H2 2018 List of Tables Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2018 Number of Products under Development by Companies, H2 2018 Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018 Number of Products under Development by Universities/Institutes, H2 2018 Products under Development by Companies, H2 2018 Products under Development by Companies, H2 2018 (Contd..1), H2 2018 Products under Development by Universities/Institutes, H2 2018 Number of Products by Stage and Target, H2 2018 Number of Products by Stage and Mechanism of Action, H2 2018 Number of Products by Stage and Route of Administration, H2 2018 Number of Products by Stage and Molecule Type, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Athersys Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Bayer AG, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Cells for Cells SA, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Commence Bio Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by CompleGen Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Cynata Therapeutics Ltd, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Faron Pharmaceuticals Oy, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by GlaxoSmithKline Plc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Hydra Biosciences Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Implicit Bioscience Ltd, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by PaxVax Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by ProMetic Life Sciences Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Savara Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by SolAeroMed Inc, H2 2018 Acute Respiratory Distress Syndrome-Pipeline by Windtree Therapeutics Inc, H2 2018 Acute Respiratory Distress Syndrome-Dormant Projects, H2 2018 Acute Respiratory Distress Syndrome-Dormant Projects, H2 2018 (Contd..1), H2 2018 Acute Respiratory Distress Syndrome-Discontinued Products, H2 2018 Single User License: Site License: Corporate User License: Athersys Inc Bayer AG Cells for Cells SA Commence Bio Inc CompleGen Inc Cynata Therapeutics Ltd Faron Pharmaceuticals Oy GlaxoSmithKline Plc Hydra Biosciences Inc Implicit Bioscience Ltd PaxVax Inc ProMetic Life Sciences Inc Savara Inc SolAeroMed Inc Windtree Therapeutics Inc Acute Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Acute Respiratory Distress Syndrome Therapeutics, Acute Respiratory Distress Syndrome Pipeline Overview, Acute Respiratory Distress Syndrome Pipeline, Acute Respiratory Distress Syndrome Pipeline Assessment |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara" |